Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated

[1]  R. Townsend,et al.  Hypertension in Cancer Patients and Survivors , 2019, JACC. CardioOncology.

[2]  Azza B El-Remessy,et al.  Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales , 2013, British journal of pharmacology.

[3]  Laura J Rasmussen-Torvik,et al.  Ideal Cardiovascular Health Is Inversely Associated With Incident Cancer: The Atherosclerosis Risk in Communities Study , 2013, Circulation.

[4]  Edward L Spitznagel,et al.  Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.

[5]  P. Libby,et al.  Inflammation: a common contributor to cancer, aging, and cardiovascular diseases—expanding the concept of cardio-oncology , 2019, Cardiovascular research.

[6]  A. Blaes,et al.  Shared Risk Factors in Cardiovascular Disease and Cancer , 2016, Circulation.

[7]  Jeroen J. Bax,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines , 2016, European journal of heart failure.

[8]  K. Bhaskaran,et al.  Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases , 2019, The Lancet.

[9]  R. Skinner,et al.  Long term cause specific mortality among 34 489 five year survivors of childhood cancer in Great Britain: population based cohort study , 2016, British Medical Journal.

[10]  P. Douglas,et al.  Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Cerhan,et al.  Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer. , 2014, Journal of the American College of Cardiology.

[12]  Timothy J Nelson,et al.  Patients with heart failure have an increased risk of incident cancer. , 2013, Journal of the American College of Cardiology.

[13]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[14]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[15]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[16]  C. Cipolla,et al.  The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. , 2010, Progress in cardiovascular diseases.

[17]  D. Levy,et al.  Abstract 12269: The Association of Cardiovascular Disease and Future Cancer , 2019 .

[18]  S. Lipshultz,et al.  Late Cardiotoxicity: Issues for Childhood Cancer Survivors , 2016, Current Treatment Options in Cardiovascular Medicine.

[19]  Jiaquan Xu,et al.  Deaths: Final Data for 2013. , 2016, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.